Peter Hermans is Professor in Molecular Infectious Diseases, appointed at Julius Centre for Health Sciences and Primary Care at University Medical Centre Utrecht (UMCU) and chairing the ‘U-TRIAL’ activities for UMCU’s priority field Infection & Immunity, which aim to further strengthen the collaboration between UMCU and private partners with prime focus on clinical studies in infectious diseases and immunological disorders (vaccines, therapeutics and diagnostics).
THERAPEUTIC AREAS AND EXPERTISE
During his academic career of more than 20 years, with appointments as scientist at the National Institute for Public Health and the Environment (RIVM) in The Netherlands, senior scientist at the Armauer Hansen Research Institute in Ethiopia, associate professor at Erasmus Medical Centre in The Netherlands and professor in Pediatrics – Molecular Infectious Diseases at Radboud University Medical Centre in The Netherlands, he has established and managed several multidisciplinary teams of up to 40 academic professionals representing medical doctors, postdocs, PhD students and technicians. He has published over 250 scientific papers in international journals in the fields of infectious diseases, microbiology, genetics, vaccinology and diagnostics, and has been serving as an editorial board member of several journals including The Lancet ID.
Between 2012 and 2019 he was appointed by Janssen – Infectious Diseases and Vaccines. The transition from the academic to the pharmaceutical world has allowed him to apply his scientific skills and expertise to develop innovative vaccines for the prevention of severe bacterial infections. In his function as Bacterial Epidemiology Lead and Liaison Manager, he has coordinated the interactions between Janssen Vaccines & Prevention and external (academic) partners. More specifically, options and scenarios for epidemiological studies and clinical efficacy testing of bacterial vaccine formulations have been developed in collaboration with the University Medical Centre Utrecht (UMCU) in Utrecht, The Netherlands.
Since 2019, he combines his academic and pharmaceutical skills and experience, and to bring them into practice in an academic medical environment. At present he is appointed at the Julius Centre for Health Sciences and Primary Care at UMCU, where he will be responsible for further strengthening the public-private partnership in the field of Infection & Immunity.
UMCU has recently established the Utrecht Trial Innovation Alliance Initiative (U-TRIAL). U-TRIAL facilitates the close cooperation of the 10 divisions and six priority fields of UMC Utrecht with external partners, including industry and governmental organizations. U-TRIAL is designed to strengthen UMC Utrecht’s pursuit of ambitious goals in clinical trials, notably Phase 2b, 3 and 4, in its priority fields, Infection & Immunity among the leading ones.
“The development of innovative vaccines and therapeutics that contribute to the wellbeing of our society is my mission and passion.”